All In Biotech

Drug Trial Radar · NCT07914738

A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)

A Phase 1, Open-Label, Pharmacokinetic Study of Lepodisiran Administered as a Single Subcutaneous Dose in the Abdomen, Thigh, or Upper Arm in Healthy Participants With High Lipoprotein(a)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Nov 2, 2026

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Nov 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study will evaluate how the body takes in lepodisiran (LY3819469) after a single injection under the skin. Researchers will compare how much lepodisiran gets into the body from each injection site. The study will also look at how safe lepodisiran is and how it affects lipoprotein(a) (Lp(a)), in healthy adults who have high Lp(a) levels. Participants will take part in the study for about 17 weeks. Participants will be admitted to the clinical research unit on Day -1 and remain confined until discharge on Day 4. The study drug will be administered on Day 1. Participants will return to the clinical research unit for outpatient visits on Days 8, 15, 29, and 57.

Conditions

  • Lipoprotein(a)

Interventions

  • LY3819469Drug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of LY3819469Time frame: Day 1 through Day 15
  2. PK: Area Under the Concentration versus Time Curve (AUC) of LY3819469Time frame: Day 1 through Day 15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lilly Centre for Clinical Pharmacology

    Singapore, Singapore · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.